In the case–control study by Pagano et al., the influence of T2DM on neurological progression also included the impact on tau protein levels in cerebrospinal fluid in 25 patients with T2DM and PD, 25 patients with PD without DM, and 14 patients with T2DM alone. The gene discussed is MAPT; the disease is Parkinson disease.